Effect on Gait Speed, Balance, Motor Symptom Rating, and Quality of Life in Those with Stage I Parkinson’s Disease Utilizing LSVT BIG®

Table 1

Participant demographics.

Characteristic	Statistic
Age (years), median (range)	75 (51–82)
Sex
Female	5
Male	4
Race
White	9
Care partner available at home	4
comorbidities, median (range)	5 (0–11)
medications, median (range)	6 (2–17)
PD medications, median range	1 (0–2)
0	1
1	5
2	3
dosing times/24 hours
2	2
3	6
4	1

Medication details: participant 1: carbidopa/levodopa and rasagiline, participants 2, 4, 5, and 7: carbidopa/levodopa, participant 3: carbidopa/levodopa and ropinirole, participant 6: none, participant 8: carbidopa/levodopa and cyclobenzaprine, and participant 9: pramipexole.